Vismodegib (GDC-0449) CAS 879085-55-9 Assay ≥99.0% (HPLC)
Shanghai Ruifu Chemical is the leading supplier of Vismodegib (GDC-0449) (CAS: 879085-55-9) with high quality.
Ruifu Chemical has been supplying APIs (Active Pharmaceutical Ingredients) and pharmaceutical intermediates more than 15 years. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service.
Purchase Vismodegib (GDC-0449), please contact us by e-mail: alvin@ruifuchem.com
| Chemical Name | Vismodegib |
| Form | Free Base |
| Synonyms | GDC-0449; 2-Chloro-N-[4-Chloro-3-(2-Pyridinyl)phenyl]-4-(Methylsulfonyl)benzamide |
| CAS Number | 879085-55-9 |
| Molecular Formula | C19H14Cl2N2O3S |
| Molecular Weight | 421.30 g/mol |
| Melting Point | 179.0-181.0℃ |
| Density | 1.440 g/cm3 |
| Storage Temperature | Store Long-Term at 2-8℃ |
| Shipping Temperature | Shipped Ambient |
| COA & MSDS | Available |
| Origin of Product | Shanghai, China |
| Shelf Life | 2 Years If Sealed and Stored Properly |
| Product Categories |
API (Active Pharmaceutical Ingredient) |
| Caution | Not For Use in Humans, Diagnostics or Therapeutics. Research Use Only. |
| Brand | Ruifu Chemical |
| Items | Specifications | Results |
| Appearance | White to Off-White Powder | Conforms |
| Water by Karl Fischer | ≤0.50% | 0.20% |
| Vismodegib Assay | ≥99.0% (HPLC) | 99.6% |
| Infrared Spectrum | Conforms to Structure | Conforms |
| NMR Spectrum | Conforms to Structure | Conforms |
| Conclusion | The product has been tested and complies with the given specifications | |
Package: Bottle, Aluminium foil bag, or according to customer's requirement.
Storage Condition: Keep the container tightly closed. Store in a cool, dry (2-8℃) and well-ventilated warehouse away from incompatible substances. Keep away from sunshine; avoid fire and heat sources; avoid moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
| HS Code | 2933 3990.99 |
Vismodegib (GDC-0449) (CAS: 879085-55-9) is one of the first anti-tumor drugs approved by the US Food and Drug Administration (FDA) for the treatment of advanced basal cell carcinoma (BCC) by Genentech Co., Ltd. on January 30, 2012. Since October 2012, Vismodegib (Erivedge) has been approved by the European Union, Switzerland, Australia, Israel, South Korea, Mexico and Ecuador.
Vismodegib (GDC-0449) (CAS: 879085-55-9) is used for the treatment of locally progressive or metastatic basal cell carcinoma in adults who have relapsed after surgery or are not amenable to surgery or radiotherapy; basal cell carcinoma (BCC) is one of the most common forms of skin cancer. It originates from the surface of the skin and does not cause pain. For regular exposure to sunlight or ultraviolet radiation skin disease is the most likely. The R & D and marketing of Vismodegib has brought good news to BCC Patients. Its clinical role is important and the target market is huge, and Vismodegib will grow into a "Giant Bomb" class (> $1 billion) drug in the future.
Vismodegib (GDC-0449) (CAS: 879085-55-9) has a novel mechanism of action and is a selective Hedgehog signaling pathway inhibitor. Although Hedgehog signaling pathway is active in early life and plays an important role in regulating human growth and development, it is not active in adults. The vast majority of patients with basal cell carcinoma (>90%) have an overactive Hedgehog signaling pathway, which is considered to be the basic molecular driver of basal cell carcinoma. It acts as a competitive Cyclopamine antagonist and acts on the transmembrane G protein-coupled receptor protein (Smoothened) in the Hedgehog signaling pathway. It can block the expression of tumor-regulated genes related to Hedgehog signaling pathway by inhibiting SMO receptors to keep transcription factors GLT-1 and GLT-2 in a non-activated state.
